To CANCER IMMUNITY Home Page

Article
 
Cancer Immunity, Vol. 2, p. 15 (7 November 2002) Submitted: 23 May 2002. Resubmitted: 15 October 2002. Accepted: 18 October 2002.
Communicated by: A Knuth

Characterization of cells prepared by dendritic cell-tumor cell fusion

Eva Gottfried1, René Krieg2, Christian Eichelberg1, Reinhard Andreesen1, Andreas Mackensen1, and Stefan W. Krause1

1Dept. of Hematology and Oncology, University of Regensburg, Regensburg, Germany
2Dept. of Pathology, University of Regensburg, Regensburg, Germany

Keywords: cultured tumor cells, dendritic cells, cell fusion, hybrid cells

 

Abstract

Dendritic cells (DCs) are professional antigen-presenting cells currently being discussed as a potent tool for antitumor vaccination strategies. The approach consisting of the in vitro generation of DC-tumor cell hybrids may be advantageous for individualized vaccines since there is no need for the determination of MHC-restricted tumor-associated antigens recognized by T cells. As recent vaccination studies gave varying results, we tested the impact of the fusion treatment on the cells used. Polyethylene glycol-induced fusion, as well as electrofusion, proved to be suitable for generating hybrid cells although at a low frequency. Of note, both methods also gave rise to DCs having phagocytosed apoptotic tumor cells. The expression of surface molecules relevant for specific T cell stimulation was not altered by the fusion procedure and the DCs were still functionally active as demonstrated by the secretion of IL-12 and the uptake of antigen. The cells were able to induce a tumor-specific T cell response in vitro and therefore deserve further investigation as potent tools for immunotherapy trials.

 

Copyright © 2002 by Stefan W. Krause